Company intelligence / Profile preview

QRD

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

QRD is a biotechnology company focused on developing novel small molecule therapeutics for the treatment of inflammatory and fibrotic diseases. The company's lead program targets GPR35, a G protein-coupled receptor with significant genetic and functional links to gastrointestinal and hepatobiliary disorders. QRD aims to address high unmet medical needs in conditions such as inflammatory bowel disease and primary sclerosing cholangitis. By leveraging deep expertise in GPCR pharmacology, the company is advancing a pipeline of potent and selective modulators. QRD's approach combines rigorous scientific validation with efficient drug discovery to bring transformative medicines to patients.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on QRD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QRD.

Explore the full profile